Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 112
Filtrar
1.
Am J Transplant ; 6(1): 150-60, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16433769

RESUMO

Rejection diagnosis by endomyocardial biopsy (EMB) is invasive, expensive and variable. We investigated gene expression profiling of peripheral blood mononuclear cells (PBMC) to discriminate ISHLT grade 0 rejection (quiescence) from moderate/severe rejection (ISHLT > or = 3A). Patients were followed prospectively with blood sampling at post-transplant visits. Biopsies were graded by ISHLT criteria locally and by three independent pathologists blinded to clinical data. Known alloimmune pathways and leukocyte microarrays identified 252 candidate genes for which real-time PCR assays were developed. An 11 gene real-time PCR test was derived from a training set (n = 145 samples, 107 patients) using linear discriminant analysis (LDA), converted into a score (0-40), and validated prospectively in an independent set (n = 63 samples, 63 patients). The test distinguished biopsy-defined moderate/severe rejection from quiescence (p = 0.0018) in the validation set, and had agreement of 84% (95% CI 66% C94%) with grade ISHLT > or = 3A rejection. Patients >1 year post-transplant with scores below 30 (approximately 68% of the study population) are very unlikely to have grade > or = 3A rejection (NPV = 99.6%). Gene expression testing can detect absence of moderate/severe rejection, thus avoiding biopsy in certain clinical settings. Additional clinical experience is needed to establish the role of molecular testing for clinical event prediction and immunosuppression management.


Assuntos
Perfilação da Expressão Gênica , Rejeição de Enxerto/diagnóstico , Transplante de Coração , Adolescente , Adulto , Idoso , Feminino , Rejeição de Enxerto/genética , Rejeição de Enxerto/patologia , Transplante de Coração/imunologia , Humanos , Terapia de Imunossupressão , Leucócitos Mononucleares/química , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/análise
2.
Minerva Cardioangiol ; 51(2): 245-55, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12783079

RESUMO

Since the 1(st) heart transplant was performed over 30 y ago, recipients have benefited from dramatic improvements in survival and quality of life following the procedure. Approximately 3 500 people worldwide now undergo heart transplantation each year. The vast majority of patients will have no limitations in their daily activities and will remain free of re-hospitalization after the 1(st) year. The median survival following heart transplant is now 9 y, and it remains the treatment of choice for children and adults with end-stage heart disease despite emerging therapies. This article will review patient selection, perioperative management issues, medical management of recipients, and future trends in the treatment of this patient population.


Assuntos
Transplante de Coração , Rejeição de Enxerto/prevenção & controle , Coração Auxiliar , Humanos , Imunossupressores/uso terapêutico , Seleção de Pacientes , Qualidade de Vida
3.
Science ; 294(5548): 1933-6, 2001 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-11729320

RESUMO

Hematopoietic stem cells (HSCs) reside predominantly in bone marrow, but low numbers of HSCs are also found in peripheral blood. We examined the fate of blood-borne HSCs using genetically marked parabiotic mice, which are surgically conjoined and share a common circulation. Parabionts rapidly established stable, functional cross engraftment of partner-derived HSCs and maintained partner-derived hematopoiesis after surgical separation. Determination of the residence time of injected blood-borne progenitor cells suggests that circulating HSCs/progenitors are cleared quickly from the blood. These data demonstrate that HSCs rapidly and constitutively migrate through the blood and play a physiological role in, at least, the functional reengraftment of unconditioned bone marrow.


Assuntos
Movimento Celular , Quimera/sangue , Hematopoese/fisiologia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/citologia , Animais , Circulação Sanguínea/fisiologia , Células-Tronco Hematopoéticas/metabolismo , Homeostase , Antígenos Comuns de Leucócito/análise , Camundongos , Fatores de Tempo
4.
Am J Physiol Cell Physiol ; 281(5): C1422-33, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11600404

RESUMO

Endothelium critically regulates systemic and pulmonary vascular function, playing a central role in hemostasis, inflammation, vasoregulation, angiogenesis, and vascular growth. Indeed, the endothelium integrates signals originating in the circulation with those in the vessel wall to coordinate vascular function. This highly metabolic role differs significantly from the historic view of endothelium, in which it was considered to be merely an inert barrier. New lines of evidence may further change our understanding of endothelium, in regard to both its origin and function. Embryological studies suggest that the endothelium arises from different sites, including angiogenesis of endothelium from macrovascular segments and vasculogenesis of endothelium from microcirculatory segments. These findings suggest an inherent phenotypic distinction between endothelial populations based on their developmental origin. Similarly, diverse environmental cues influence endothelial cell phenotype, critical to not only normal function but also the function of a diseased vessel. Consequently, an improved understanding of site-specific endothelial cell function is essential, particularly with consideration to environmental stimuli present both in the healthy vessel and in development of vasculopathic disease states. The need to examine endothelial cell phenotypes in the context of vascular function served as the basis for a recent workshop sponsored by the National Heart, Lung, and Blood Institute (NHLBI). This report is a synopsis of pertinent topics that were discussed, and future goals and research opportunities identified by the participants of the workshop are presented.


Assuntos
Endotélio Vascular/patologia , Cardiopatias/patologia , Doenças Hematológicas/patologia , Pneumopatias/patologia , Animais , Comunicação Celular/fisiologia , Endotélio Vascular/citologia , Cardiopatias/sangue , Doenças Hematológicas/sangue , Humanos , Pneumopatias/sangue , Fenótipo
5.
Nat Med ; 7(7): 833-9, 2001 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11433349

RESUMO

We provide anatomic and functional evidence that nicotine induces angiogenesis. We also show that nicotine accelerates the growth of tumor and atheroma in association with increased neovascularization. Nicotine increased endothelial-cell growth and tube formation in vitro, and accelerated fibrovascular growth in vivo. In a mouse model of hind-limb ischemia, nicotine increased capillary and collateral growth, and enhanced tissue perfusion. In mouse models of lung cancer and atherosclerosis, we found that nicotine enhanced lesion growth in association with an increase in lesion vascularity. These effects of nicotine were mediated through nicotinic acetylcholine receptors at nicotine concentrations that are pathophysiologically relevant. The endothelial production of nitric oxide, prostacyclin and vascular endothelial growth factor might have a role in these effects.


Assuntos
Arteriosclerose/complicações , Carcinoma Pulmonar de Lewis/irrigação sanguínea , Carcinoma Pulmonar de Lewis/patologia , Neoplasias Pulmonares/irrigação sanguínea , Neoplasias Pulmonares/patologia , Neovascularização Patológica/etiologia , Nicotina/farmacologia , Animais , Arteriosclerose/patologia , Camundongos , Camundongos Endogâmicos C57BL
6.
Am J Respir Crit Care Med ; 164(2): 302-6, 2001 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-11463605

RESUMO

Previous studies show that uridine 5'-triphosphate (UTP), a P2Y(2) receptor agonist, is effective at acutely enhancing mucociliary clearance in healthy, nonsmoking adults. UTP solution for inhalation is being developed by Inspire Pharmaceuticals under the compound number INS316. In a double-blind, randomized, crossover, placebo-controlled study we tested the single-dose effect of UTP in chronic smokers with mild chronic bronchitis (n = 15) by measuring the clearance of (99m)Tc-Fe(2)O(3) particles (4.0 microm mass median aerodynamic diameter [MMAD]) after inhalation of nebulized placebo (0.9% saline) and two doses of UTP (20 and 100 mg in the nebulizer). On each study day, gamma camera scanning was performed over a 2-h period. After an initial deposition scan, subjects inhaled placebo or UTP during the first 20 min of scanning. Analysis of whole lung clearance showed that the retention-time curves for each day were biphasic and that the earliest break point in the average curves occurred at 50 min. Mean particle clearance rate (Clr in %/min) through 50 min for placebo treatment was Clr = 0.65 +/- 0.27 whereas treatment with UTP showed Clr significantly increased to 0.95 +/- 0.48 and 0.93 +/- 0.44 for the 20-mg and 100-mg dose respectively, p < 0.005 for both as compared with placebo. These data show that mucociliary clearance associated with mild chronic bronchitis is acutely improved with minimal doses of aerosolized UTP, presumably because of its stimulation of ciliary beating and hydration of airway secretions.


Assuntos
Bronquite/tratamento farmacológico , Depuração Mucociliar/efeitos dos fármacos , Uridina Trifosfato/administração & dosagem , Administração por Inalação , Adulto , Bronquite/fisiopatologia , Doença Crônica , Estudos Cross-Over , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença
7.
Blood ; 97(10): 2998-3003, 2001 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-11342423

RESUMO

Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymphoma at high risk for tumor lysis. Patients received the assigned uric acid-lowering agent for 5 to 7 days during induction chemotherapy. The primary efficacy end point was to compare the area under the serial plasma uric acid concentration curves during the first 96 hours of therapy (AUC(0-96)). Fifty-two patients were randomized at 6 sites. In an intent-to-treat analysis, the mean uric acid AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the allopurinol group (P <.0001). The rasburicase versus allopurinol group experienced a 2.6-fold (95% CI: 2.0-3.4) less exposure to uric acid. Four hours after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% versus 12% reduction (P <.0001) of initial plasma uric acid levels. No antirasburicase antibodies were detected at day 14. This randomized study demonstrated more rapid control and lower levels of plasma uric acid in patients at high risk for tumor lysis who received rasburicase compared to allopurinol. For pediatric patients with advanced stage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allopurinol during initial chemotherapy.


Assuntos
Alopurinol/uso terapêutico , Leucemia/complicações , Linfoma/complicações , Síndrome de Lise Tumoral/prevenção & controle , Urato Oxidase/uso terapêutico , Ácido Úrico/sangue , Adolescente , Alopurinol/administração & dosagem , Alopurinol/efeitos adversos , Criança , Pré-Escolar , Creatinina/sangue , Drogas em Investigação , Feminino , Humanos , Lactente , Rim/fisiopatologia , Cinética , Leucemia/tratamento farmacológico , Leucemia/fisiopatologia , Linfoma/tratamento farmacológico , Linfoma/fisiopatologia , Masculino , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Insuficiência Renal/etiologia , Fatores de Risco , Resultado do Tratamento , Urato Oxidase/administração & dosagem , Urato Oxidase/efeitos adversos , Urato Oxidase/metabolismo
8.
Bone Marrow Transplant ; 20(3): 247-9, 1997 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9257894

RESUMO

In this case report, we evaluate the efficacy of allogeneic bone marrow transplantation (BMT) in a 7-month-old female with the infantile form of Alexander's disease. Based on research that describes Alexander's disease as a leukodystrophy which may result from an unidentified enzyme deficiency, we attempted marrow transplantation to reverse or arrest the patient's neurological deterioration. Despite an initial return to her pretransplant neurological state, the patient's neurological status deteriorated. Marrow transplantation was not effective in changing her prognosis with Alexander's disease.


Assuntos
Transplante de Medula Óssea , Doenças Desmielinizantes/terapia , Doenças Desmielinizantes/patologia , Doenças Desmielinizantes/fisiopatologia , Feminino , Humanos , Lactente , Transplante Homólogo
10.
Bone Marrow Transplant ; 18 Suppl 3: S39-44, 1996 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8971407

RESUMO

The most effective treatment currently available for children with severe aplastic anemia is bone marrow transplantation using a sibling donor who is completely matched with the patient at the major histocompatibility complex. Only a minority of patients, however, will have such a donor and other treatments which have been used include the use of single agent immunosuppression, multi-agent immunosuppression, multi-agent immunosuppression with hemopoietic growth factors, and the use of allogeneic stem cell transplantation using mismatched family members, unrelated individuals or placental blood. Of these approaches the most promising appears to be the use of combination immunosuppressive therapy plus hemopoietic growth factors. This paper reviews the current results obtained in using these various methods of treating children with severe aplastic anemia who lack a matched sibling donor.


Assuntos
Anemia Aplástica/terapia , Transplante de Medula Óssea , Fatores de Crescimento de Células Hematopoéticas/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Imunossupressores/uso terapêutico , Anemia Aplástica/tratamento farmacológico , Soro Antilinfocitário/uso terapêutico , Transplante de Medula Óssea/efeitos adversos , Criança , Ensaios Clínicos como Assunto , Terapia Combinada , Ciclosporina/uso terapêutico , Sangue Fetal/citologia , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/prevenção & controle , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Histocompatibilidade , Humanos , Interleucina-3/uso terapêutico , Metilprednisolona/uso terapêutico , Núcleo Familiar , Proteínas Recombinantes de Fusão/uso terapêutico , Linfócitos T , Transplante Homólogo
11.
Bone Marrow Transplant ; 18(3): 533-40, 1996 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8879614

RESUMO

We report 18 patients with Down's syndrome who underwent bone marrow transplantation, and review nine previously published patients. The indications for transplant in the combined group of 27 patients were acute lymphoblastic leukaemia in 14 cases (52%), acute myeloid leukaemia in 11 cases (41%) and aplastic anemia in two cases (7%). Transplants were autologous in five cases (19%) and allogeneic in 22 cases (81%); of the 22 allogeneic transplants, 16 donors were HLA-matched siblings. In all patients the conditioning regimen included total body irradiation of 7.5 Gy or more, and/or contained cyclophosphamide of 120 mg/kg or more. Seven patients (26%) had fatal pulmonary disease including pneumonitis and pulmonary hemorrhage. Five patients (19%) had significant airway problems including three with severe mucositis who required intubation for airway protection, one with severe mucositis with partial airway obstruction that required observation in the intensive care unit but did not require intubation, and one with Candida albicans laryngitis with development of a glottic web. Nineteen patients (70%) survived beyond 100 days post-transplant. There was no clear association between 100-day survival and the use of any particular agent or regimen used for conditioning or graft-versus-host disease prophylaxis, and the majority of patients tolerated high-dose cyclophosphamide, high-dose cytosine arabinoside, high-dose busulfan, total body irradiation, cyclosporin A, and methotrexate. There appeared to be more early deaths in patients who received the combination of cyclophosphamide and total body irradiation, compared with those receiving the combination of busulfan and cyclophosphamide or those receiving the combination of cytosine arabinoside and total body irradiation. Also, the use of methotrexate was associated with a greater number of early deaths, compared with cyclosporin A. At 3 years, life table estimates of freedom from relapse, relapse-free survival and survival were 75%, 44% and 48%, respectively. The estimated cumulative risk of death due to a non-leukaemic cause at 3 years was 39%. The data show that Down syndrome patients can tolerate the commonly used transplant conditioning regimens with acceptable toxicity; however, there is a strong suggestion in the data that the rates of life-threatening and fatal toxicity are higher than would be expected to occur in patients without Down's syndrome. Patients with Down's syndrome may have a predisposition to fatal pulmonary complications and reversible airway problems during the immediate post-transplant period.


Assuntos
Anemia Aplástica/terapia , Transplante de Medula Óssea , Síndrome de Down/complicações , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Adulto , Transplante de Medula Óssea/efeitos adversos , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Condicionamento Pré-Transplante , Resultado do Tratamento
12.
Bone Marrow Transplant ; 17(2): 287-9, 1996 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8640182

RESUMO

The early toxicity, incidence of graft-versus-host disease (GVHD) and long-term follow-up were evaluated in two children with Down syndrome (DS) treated for acute lymphoblastic leukemia (ALL) in second complete remission by HLA-matched sibling allogeneic bone marrow transplantation (BMT). Preparative conditioning therapy consisted of cytosine arabinoside (Ara-C) and fractionated total body irradiation (F-TBI) and GVHD prophylaxis of cyclosporin A. The conditioning regimen was well tolerated, the only acute complication being mild mucositis. Engraftment (polymorphonuclear cells >500/microliter) was documented by day +17 in both patients. One child remains in continuous complete remission, without medical problems, 60 months after BMT. The second patient died from complications associated with chronic GVHD 21 months following BMT. Ara-C and F-TBI is a well-tolerated preparative regimen for children with DS undergoing allogeneic BMT.


Assuntos
Transplante de Medula Óssea , Citarabina , Síndrome de Down/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras B/terapia , Irradiação Corporal Total , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Pré-Escolar , Terapia Combinada , Irradiação Craniana , Daunorrubicina/administração & dosagem , Evolução Fatal , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Masculino , Mercaptopurina/administração & dosagem , Metotrexato/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/radioterapia , Prednisona/administração & dosagem , Terapia de Salvação , Transplante Homólogo , Vincristina/administração & dosagem
13.
Am J Clin Nutr ; 62(2): 463S-470S, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7625361

RESUMO

We tested the hypothesis that an increased content of n-6 polyunsaturated fatty acids (principally linoleic acid) in an atherogenic diet of nonhuman primates would decrease atherosclerosis by modifying the composition and decreasing the concentration of plasma low-density lipoprotein (LDL). A species readily susceptible to diet-induced atherosclerosis (cynomolgus monkey) was compared with a less-susceptible species (African green monkey) with dietary cholesterol concentration and saturated or polyunsaturated fat (40% of energy) as variables. In both species, cholesterol concentrations in whole plasma, LDL, and high-density lipoprotein (HDL) were 20-30% lower when polyunsaturated fat was fed, whereas dietary cholesterol increased LDL cholesterol three- to fourfold. LDL was enriched in cholesteryl oleate when saturated fat and cholesterol were fed. Dietary linoleic acid prevented cholesteryl oleate enrichment and promoted cholesteryl linoleate accumulation in LDL. At the same plasma cholesterol concentration, cynomolgus monkeys had higher LDL cholesterol and lower HDL-cholesterol concentrations than did African green monkeys. LDL particle size was significantly (P < 0.001) larger in the group of cynomolgus monkeys fed polyunsaturated fat but tended to be smaller in African green monkeys fed polyunsaturated fat. Dietary polyunsaturated fat protected against coronary artery atherosclerosis in both species. Thus, LDL particle size, per se, was not atherogenic; instead, coronary artery atherosclerosis and cholesteryl oleate enrichment of LDL were more highly correlated. This outcome suggests that information about LDL composition may be more important for understanding the pathogenesis of atherosclerosis than previously suspected.


Assuntos
Arteriosclerose/dietoterapia , Arteriosclerose/prevenção & controle , Gorduras Insaturadas na Dieta/farmacologia , Ácidos Graxos Insaturados/uso terapêutico , Lipoproteínas LDL/sangue , Animais , Arteriosclerose/sangue , Chlorocebus aethiops , HDL-Colesterol/sangue , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ácidos Graxos Insaturados/normas , Ácido Linoleico , Ácidos Linoleicos/normas , Ácidos Linoleicos/uso terapêutico , Lipoproteínas HDL/sangue , Macaca fascicularis , Masculino
15.
Blood ; 85(4): 879-84, 1995 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-7849310

RESUMO

Seven of 21 patients with sickle cell anemia developed neurologic complications 5 to 243 days (median, 33 days) after allogeneic marrow transplantation. Among these 7 patients, indications for transplantation included either a past history of stroke (4 patients) or recurrent severe vaso-occlusive events (3 patients). All received marrow from an HLA-identical sibling after preparation with busulfan and cyclophosphamide, and in 4 patients with antithymocyte globulin. Five of 6 patients developing seizures received anticonvulsant and supportive treatment with resolution of neurologic abnormalities. Three patients experienced intracranial bleeding, which was fatal in two. Of the 14 patients free of neurologic complications, 4 patients had experienced stroke before transplantation. However, among all patients with prior stroke, the incidence of intracranial hemorrhage was 38% (3/8), whereas none of the 13 patients without prior stroke developed posttransplant intracranial bleeding (P = .026). We conclude that patients with sickle cell anemia are at increased risk for neurologic complications after marrow ablative therapy and that patients with prior stroke are at increased risk for intracranial hemorrhage. Transplantation of patients before the onset of overt stroke may reduce this risk.


Assuntos
Anemia Falciforme/terapia , Transplante de Medula Óssea/efeitos adversos , Hemorragia Cerebral/etiologia , Convulsões/etiologia , Adolescente , Adulto , Anticonvulsivantes/uso terapêutico , Soro Antilinfocitário/uso terapêutico , Bussulfano/uso terapêutico , Transtornos Cerebrovasculares/complicações , Criança , Pré-Escolar , Ciclofosfamida/uso terapêutico , Feminino , Teste de Histocompatibilidade , Humanos , Masculino , Convulsões/tratamento farmacológico , Transplante Homólogo , Doenças Vasculares/complicações
17.
Am J Pediatr Hematol Oncol ; 16(1): 11-7, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8311166

RESUMO

PURPOSE: We have reviewed the results of bone marrow transplantation in 30 patients with thalassemia major who were treated in the United States. PATIENTS AND METHODS: Ten patients who underwent transplantation in Seattle and 20 patients from five other U.S. centers were identified through a survey of the International Bone Marrow Transplant Registry. These transplants were performed between November 1981 and April 1992 in patients with diverse ethnic backgrounds and ranged in age from 6 months to 14 years (median 4.0 years). Twenty-seven of the 30 patients received marrow from a human leukocyte antigen (HLA)-identical sibling or other family member, one patient received HLA-matched marrow from an unrelated donor, and two patients were given haploidentical but HLA-mismatched marrow from a related donor. Cytoreductive (preparative) therapy varied among institutions and pretransplant risk categories. In general, patients were given busulfan (12-24 mg/kg) or dimethylmyleran (5 mg/kg) in combination with cyclophosphamide (120-240 mg/kg). A subset of patients were given total body irradiation (TBI) at a dose of 720 cGy followed by cyclophosphamide (120 mg/kg). RESULTS: Sixteen of 27 patients (59%) who received marrow from an HLA-identical family member are event-free survivors, with a duration of follow-up ranging from 2 months to > 10 years after transplantation. Six of these 27 patients (22%) had recurrence of thalassemia and five (19%) died. The estimated actuarial rate of thalassemia recurrence was 24% and the rate of event-free survival was 57%. Only one of the three patients who received marrow from HLA-nonidentical or unrelated donors survives event-free. Liver biopsies were not routinely performed before transplant. Thus, classification of patients into Lucarelli risk groups was not possible. A modified risk classification was devised by using liver size and iron status assessed by the regularity of chelation and the serum ferritin level. With use of this classification, there was no significant difference in event-free survival between transplant risk groups. CONCLUSIONS: The findings observed in this small series of patients confirms that thalassemia can be cured with bone marrow transplantation. Although most patients are event-free survivors, a significant number experienced recurrence of their disease. A cooperative multicenter trial of U.S. transplant centers may be necessary to evaluate the use of marrow transplantation for thalassemia and to determine optimal treatment.


Assuntos
Transplante de Medula Óssea , Talassemia beta/terapia , Adolescente , Criança , Pré-Escolar , Ciclofosfamida/uso terapêutico , Feminino , Doença Enxerto-Hospedeiro/etiologia , Humanos , Lactente , Masculino , Taxa de Sobrevida , Estados Unidos , Irradiação Corporal Total , Talassemia beta/mortalidade
18.
Am J Pediatr Hematol Oncol ; 16(1): 22-6, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8311168

RESUMO

PURPOSE: As of June 1992, five patients with sickle cell disease had been treated by matched sibling bone marrow transplantation in the United States. PATIENTS AND METHODS: Three patients underwent transplantations for complications related to sickle cell disease, two with previous cerebrovascular accidents (CVAs) and one who had had multiple severe vasoocclusive crises. Two patients had other indications for allogeneic bone marrow transplantation: one had acute myeloid leukemia and the other had Morquio's disease. The patients' ages ranged from 3 to 10 years, and four were girls. Ages of the donors ranged from 4 to 13 years; four of the donors were boys and three carried the sickle cell trait. For four patients, the preparative regimen consisted of busulfan and cyclophosphamide given either alone or combined with antithymocyte globulin (ATG). The patient with leukemia was prepared with cyclophosphamide and total body irradiation (TBI). The regimens for prophylaxis of graft-versus-host disease (GVHD) included various combinations of cyclosporine A, methotrexate, and prednisone. RESULTS: The patient with Morquio's disease failed to engraft but underwent a successful retransplantation from the same donor. All patients eventually demonstrated donor engraftment and the donor's hemoglobin electrophoretic pattern posttransplant. Two patients had moderately severe GVHD of the skin and gastrointestinal tract, which resolved with prednisone therapy. One of these patients developed transient chronic GVHD involving the skin. Other acute complications included mild venoocclusive disease of the liver, central line infection with bacteremias, uterine hemorrhage in one patient, and pseudomonas sepsis in another. CONCLUSIONS: Both patients who underwent transplantation after CVAs have experienced subsequent neurological events. However, with a median follow-up of 16 months (range 8 months to 9.3 years), all patients are surviving in good to excellent clinical condition and appear to have benefitted from treatment by bone marrow transplantation.


Assuntos
Anemia Falciforme/terapia , Transplante de Medula Óssea , Adolescente , Transplante de Medula Óssea/efeitos adversos , Criança , Pré-Escolar , Feminino , Doença Enxerto-Hospedeiro/etiologia , Humanos , Masculino , Estados Unidos
19.
Neurosurgery ; 33(6): 1018-24; discussion 1024-5, 1993 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8133986

RESUMO

We prospectively and retrospectively reviewed a series of 780 patients who presented to the University of Southern California/Los Angeles County Medical Center with a diagnosis of gunshot wound to the brain during an 8-year period. Of these, 105 were children ranging in age from 6 months to 17 years. Injuries were gang related in 76 (72%) children and adolescents. Stepwise linear regression analysis was used to formulate a predictive model of outcome in this population. Patient age (F = 10.92), sex (F = 9.32), occipital entry site (F = 8.17), bihemispheric injury (F = 8.50), and admission Glasgow Coma Scale (F = 69.91) were all found to correlate with outcome (P < 0.05). Significant differences between pediatric and adult populations were noted in transit time, entrance site, and age-related outcome. Occipital or assassination-type wounds were most common in children. In addition, a younger age was associated with poor outcome (P < 0.0001). We describe both the economic and racial trends in our population of patients in addition to weapon type and toxicological evaluation. The Department of Neurological Surgery is becoming directly involved in providing information to children at the junior high school level regarding gang activity and brain and spinal cord injury. In conjunction with the Community Youth Gang Services Organization and Think First Organization, we are attempting to integrate prevention through education and community mobilization. This is a plan aimed at informing and recovering the youth affected by gangs.


Assuntos
Lesões Encefálicas/epidemiologia , Ferimentos por Arma de Fogo/epidemiologia , Adolescente , Lesões Encefálicas/etiologia , Lesões Encefálicas/terapia , Área Programática de Saúde , Criança , Pré-Escolar , Terapia Combinada , Comorbidade , Etnicidade , Feminino , Armas de Fogo/estatística & dados numéricos , Escala de Coma de Glasgow , Homicídio/estatística & dados numéricos , Humanos , Lactente , Los Angeles/epidemiologia , Masculino , Prognóstico , Estudos Prospectivos , Análise de Regressão , Estudos Retrospectivos , Comportamento Social , Fatores Socioeconômicos , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Resultado do Tratamento , Ferimentos por Arma de Fogo/terapia
20.
Endocrinol Metab Clin North Am ; 22(3): 617-29, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8243451

RESUMO

As the survival of children with cancer improves, attention must now be focused on understanding and preventing long-term toxicities of treatment and improving the quality of survival. Gonadal toxicity is relatively common, particularly with radiation therapy and alkylating agents. Continued research into the pathogenesis and prevention of gonadal toxicities needs to be included in future treatment strategies for childhood cancer. This will require a multidisciplinary approach with input from pediatric hematologist/oncologists, radiation oncologists, and pediatric endocrinologists.


Assuntos
Antineoplásicos/efeitos adversos , Gônadas/efeitos dos fármacos , Gônadas/efeitos da radiação , Radioterapia/efeitos adversos , Adolescente , Antineoplásicos/uso terapêutico , Feminino , Humanos , Masculino , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...